Current Bispecific Landscape and Patient Eligibility Considerations

Dr. Nooka reviews the current approved bispecific antibody landscape, noting that MajesTEC-1, MajesTEC-3, and MonumenTAL-1 trials led to conditional approvals for the same indication: patients with 4 or more prior lines of therapy including proteasome inhibitor, immunomodulatory drug, and CD38 antibody exposure. These agents demonstrate response rates of 60-70% in heavily pretreated populations, representing a dramatic improvement from historical expectations of 30% response rates and 3-4 month median progression-free survival in comparable patient populations from decades past.

The transformative impact of bispecific antibodies extends beyond response rates to durability. Current agents deliver median progression-free survival of 12-18 months even in heavily pretreated patients. More importantly, Dr. Nooka emphasizes the exceptional duration of response among responders: while 60 of 100 patients may respond, those responding patients maintain their responses for extended periods, creating the "beauty" of these therapeutic agents.

This durability principle becomes even more significant in the early relapse setting, where 80% of patients respond and achieve long, durable remissions. Dr. Nooka speculates that if these remissions extend to the 5-6 year timeframe, strategies for finite treatment duration and maintenance discontinuation become viable, representing substantial progress toward functional cure scenarios.

Regarding treatment selection between CAR-T and bispecific approaches, Dr. Nooka acknowledges patient preference limitations with CAR-T therapy. Although CAR-T represents optimal treatment and is offered to eligible patients in frontline settings as a "one and done" approach, only approximately 30% of patients accept this option when presented to 100 eligible candidates. Although CAR-T utilization is increasing, it remains limited to a subset of patients requiring therapy in the relapse setting.

This creates substantial opportunity for bispecific-CD38 antibody combinations, particularly for patients unwilling to pursue CAR-T therapy. Dr. Nooka concludes that every patient becomes eligible for BCMA bispecific and CD38 antibody combinations, providing a broadly applicable treatment approach for the majority of patients in the early relapse setting who cannot or will not pursue CAR-T therapy.